Moleculin Biotech (MBRX) investor relations material

Company overview and business model

• Focuses on late-stage pharmaceutical development, primarily evaluating Annamycin, a next-generation anthracycline, in a pivotal Phase 3 trial for relapsed/refractory acute myeloid leukemia (AML).

• Holds two additional technology portfolios for hard-to-treat cancers and viruses, with clinical and preclinical research collaborations at academic institutions.

• Drug candidates are based on discoveries licensed from the University of Texas MD Anderson Cancer Center.

• Three core technologies have produced drug candidates that have completed or are in advanced clinical trials.

Financial performance and metrics

• As of March 11, 2026, 5,336,350 shares of common stock were outstanding.

• The closing price of common stock on March 26, 2026, was $2.43 per share on Nasdaq.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders.

• May receive up to $15.3 million in gross proceeds if all warrants are exercised for cash at $2.3976 per share.

• Proceeds from warrant exercises will be used for working capital and general corporate purposes, with management retaining broad discretion over allocation.